Abstract:Objective: To study the expression of α5β1 integrin and phosphorylated ERK1/2(p-ERK1/2) in non-small cell lung cancer (NSCLC), and the effect of α5β1 integrin and ERK signal transduction pathway on proliferation and migration of A549 cells. Method: The expression of α5β1 integrin and p-ERK1/2 in 41 specimens of NSCLC, and 15 controled specimens were determined by immunohistochemical assay and Western blot analysis. The correlation between the results of two methods was then analyzed. A549 cells were cultured in vitro, with anti-α5β1 and ERK. inhibitor PD98059 as the tool drugs. The proliferation and apoptosis of the A549 cells were measured with the MTT assay and Annexin-V FITC PI double staining, respectively. The protein expression level of MMP-9 was measured with Western blot analysis. The protein expression levels of ERK1/2 were detected by Western blot analysis and the expression levels of ERK1/2 mRNA was measured by RT-PCR. Result: The expression of α5β1 integrin and p-ERK1/2 was significantly higher in NSCLC (58.53% and 65.52%, respectively) compared with that in the normal lung tissue (26.67% and 20.00% respectively). There was also a positive correlation of α5β1 integrin and p-ERK1/2 expression with pathological characteristics (P = 0.000, P = 0.030), lymph node metastasis (P = 0.014, P = 0.000), and clinical stage (P = 0.027, P = 0.038). The expression of α5β1 integrin was positively correlated with p-ERK1/2 expression (r = 0.375, P < 0.05). The anti-α5β1 and ERK inhibitor PD98059 could inhibit the proliferation of A549 cells, resulting in an increase of the percentage in the early apoptotic cells, and down-regulated the expression of MMP-9. In addition, the anti-α5β1 could inhibit the phosphorylated ratio of ERK by down-regulating the expression of ERK mRNA and the relative proteins. Conclusion: The positive rates of α5β1 integrin and p-ERK1/2 are higher in NSCLC than in the normal lung tissue. Anti-α5β1 can down-regulate the expression of ERK mRNA and the phosphorylated ratio, and can inhibit the proliferation of A549 cells and down-regulate the expression of MMP-9. This indicates that the α5β1 integrin-mediated ERK signal transduction pathway might lead to the abnormal proliferation and migration of A549 cells.

High Expression of WNT5A in Small Cell Lung Cancer and Promotion of Cell Migration by Phosphorylation of JNK

CXCL5 Regulation of Proliferation and Migration in Human Non-Small Cell Lung Cancer Cells

Overexpression of Wnt5a Promotes Angiogenesis in NSCLC.

Overexpression of ADAMTS5 Can Regulate the Migration and Invasion of Non-Small Cell Lung Cancer

WNT5A/JNK Signaling Regulates Pancreatic Cancer Cells Migration by Phosphorylating Paxillin

WNT5B promotes the malignant phenotype of non-small cell lung cancer via the FZD3-DVL3-RAC1-PCP-JNK pathway

[PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer by Regulating of PI3K/AKT Pathway].

Wnt5A expression is associated with the tumor metastasis and clinical survival in cervical cancer.

WNT5A promotes the metastasis of esophageal squamous cell carcinoma by activating the HDAC7/SNAIL signaling pathway

Effect of α5β1 Integrin and ERK Signaling Pathway on Non-small Cell Lung Cancer

Expression of Molecular Factors Correlated with Metastasis in Small Cell Lung Cancer and Their Significance

The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer.

WNT5A Promotes Stemness Characteristics in Nasopharyngeal Carcinoma Cells Leading to Metastasis and Tumorigenesis.

Expression of Fli-1 and the Proliferation and Survival of Small Cell Lung Cancer Cells.

USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition Via Wnt/β-Catenin Pathway

Wnt5a and CCL25 Promote Adult T-cell Acute Lymphoblastic Leukemia Cell Migration, Invasion and Metastasis

[Expression and Role of CXC Chemokine 5 in Liver Cancer Cells].

SNF5 Promotes Cell Proliferation and Immune Evasion in Non-Small Cell Lung Cancer

WNT5A in Cancer: A Pan-Cancer Analysis Revealing Its Diagnostic and Prognostic Biomarker Potential

The expression of CXCL5 in bladder cancer and its clinical significance

CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer